TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02391623
Drug: PF-06427878
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
Study: NCT03813563
Drug: PLA
Normalized name: MPLA
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlasmaLyte
Study: NCT02448901
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In vitro study. Various concentrations of Edoxoban added to blood sample and tested
Study: NCT03719560
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic cytarabine
Study: NCT03233776
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
Study: NCT00813956
Drug: gemcitabine plus carboplatin plus BSI-201
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv, 3 week cycles
Study: NCT00724971
Drug: Inotuzumab Ozogamicin (CMC-544)
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
Study: NCT00724971
Drug: Rituximab (Rituxan)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
Study: NCT02331134
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
Study: NCT02520934
Drug: Miglustat
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: combine miglustat and ERT to see if neurologic manifestations can be improved
Study: NCT02520934
Drug: ERT
Normalized name: Axert
DrugBank: Almotriptan (DB00918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enzyme replacement therapy
Study: NCT03250962
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
Study: NCT00003342
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003342
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003342
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03250962
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study: NCT04533841
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
Study: NCT00298610
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous Artesunate (2.4 mg/kg) once a day for three days
Study: NCT00298610
Drug: Malarone
Normalized name: Malarone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
Study: NCT00337298
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 (5mg) tablet daily, given 14 days totally before measure of outcome.
Study: NCT00337298
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril 10 mg given daily for 14 days and then outcome was measured.
Study: NCT03299946
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
Study: NCT03299946
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
Study: NCT03658330
Drug: Ketamine + Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
Study: NCT03464058
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01816659
Drug: Metformin ER
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
Study: NCT04533841
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol
Study: NCT00840645
Drug: YM178
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01884337
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01111981
Drug: Clobetasol Propionate 0.05% Emollient Foam
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
Study: NCT00506051
Drug: ZD6474 (vandetanib) 100mg
Normalized name: vandetanib 100 MG
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily oral tablet
Study: NCT00506051
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT00506051
Drug: ZD6474 (vandetanib) 300mg
Normalized name: vandetanib 300 MG
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04116502
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg of ruxolitinib twice daily (bd)
Study: NCT04116502
Drug: Hydroxycarbamide
Normalized name: Hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Via standard hospital mechanisms
Study: NCT04116502
Drug: Interferon-Alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any formulation, via standard hospital mechanisms
Study: NCT01455428
Drug: Lyrica (pregabalin)
Normalized name: pregabalin Oral Capsule [Lyrica]
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Study: NCT00301067
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
Study: NCT01062451
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg taken orally from days 0 through 7.
Study: NCT01062451
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg taken orally from days 0 through 7.
Study: NCT01269541
Drug: Mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical in the nose 3 times daily for 5 days
Study: NCT03969706
Drug: Abemaciclib 200 MG
Normalized name: abemaciclib 200 MG
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
Study: NCT00151762
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00026468
Drug: exisulind
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04004507
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Sterile Ophthalmic Solution
Study: NCT01806337
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation after CHOP induction
Study: NCT02200822
Drug: RAAS blockers
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
Study: NCT02756624
Drug: AC-170 Vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02783586
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of bupivacaine with adrenaline
Study: NCT03588572
Drug: Venlafaxine hydrochloride capsules
Normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
Study: NCT01058174
Drug: micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01058174
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01058174
Drug: liposomal amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01058174
Drug: caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT02823145
Drug: ZX008 (Fenfluramine Hydrochloride)
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00478972
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tablet, oral administration
Study: NCT03830918
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03830918
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01729598
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: generic valproic acid tablets packaged in placebo-matched capsules.
Study: NCT00387660
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT00387660
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02126904
Drug: IVA group
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01316302
Drug: Pristiq
Normalized name: Pristiq
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dose, 50-100mg QD, for 12 weeks.
Study: NCT00789737
Drug: Welchol
Normalized name: Welchol
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Welchol 625mg tablets
Study: NCT01676415
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study
Study: NCT03520660
Drug: Epclusa
Normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sofosbuvir/velapatasvir combination (Epclusa)
Study: NCT00443430
Drug: methotrexate - etanercept - prednisolone arm
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
Study: NCT00184912
Drug: Technetium-TC99m-labeled Annexin A5
Normalized name: TECHNETIUM TC99M TETROFOSMIN
DrugBank: Tetrofosmin (DB11180)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04652492
Drug: Tislelizumab in combination with cTACE
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
Study: NCT00053846
Drug: buspirone hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
Study: NCT01168804
Drug: bendamustine plus bortezomib plus dexamethasone
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
Study: NCT01663740
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
Study: NCT03837756
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT03837756
Drug: Lefitolimod
Normalized name: Lefitolimod
DrugBank: Lefitolimod (DB15061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A TLR9 agonist administered s.c. once weekly for 8 weeks.
Study: NCT04624893
Drug: Polatuzumab Vedotin-Piiq
Normalized name: polatuzumab vedotin-piiq
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
Study: NCT01676415
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study.
Study: NCT03855917
Drug: Sofosbuvir 400mg [Sovaldi]
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four weeks.
Study: NCT03855917
Drug: Glecaprevir/pibrentasvir (300mg/120mg)
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four weeks.
Study: NCT04292119
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days.
Study: NCT04292119
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days.
Study: NCT04292119
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib will be taken orally twice daily for 28 days.
Study: NCT04292119
Drug: TNO155
Normalized name: SHP2 inhibitor TNO155
DrugBank: Batoprotafib (DB19137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNO155 will be taken orally once daily for 14 days.
Study: NCT03008590
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 4.5 mg capsule each evening
Study: NCT00829166
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Study: NCT00829166
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Study: NCT04338022
Drug: Evobrutinib
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib twice daily (BID) in DBTP.
Study: NCT04338022
Drug: Placebo (match to Teriflunomide)
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo match to Teriflunomide once daily in DBTP.
Study: NCT04338022
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Teriflunomide once daily in DBTP.
Study: NCT01968044
Drug: Gemigliptin
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01968044
Drug: Placebo to Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02084134
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5mg every 6 hours for a total of four doses
Study: NCT01555463
Drug: Azelaic acid foam, 15% (BAY39-6251)
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid twice daily topical application
Study: NCT01555463
Drug: Vehicle foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily topical application
Study: NCT04436510
Drug: Verdiperstat
Normalized name: Verdiperstat
DrugBank: Verdiperstat (DB12440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily
Study: NCT01728272
Drug: blood concentration of metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: measure blood concentration of metoprolol
Study: NCT02154269
Drug: Treatment with G-CSF (Granulocyte colony stimulating factor)
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
Study: NCT00841295
Drug: Parenteral supplementation with sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral supplementation with an equivalent volume of sterile water
Study: NCT01649284
Drug: afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40, 30, and 20 mg film-coated tablets
Study: NCT02332031
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
Study: NCT00830427
Drug: PF-00610355
Normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg, QD, dry powder inhaler
Study: NCT00830427
Drug: PF - 00610355
Normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg, QD, dry powder inhaler
Study: NCT02018055
Drug: Aspirin+Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
Study: NCT02018055
Drug: Aspirin+Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
Study: NCT00830427
Drug: PF - 00610355
Normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mcg, QD, dry powder inhaler